• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

化疗引起的中性粒细胞减少症在前瞻性卵巢癌一线治疗中的预后作用。MITO2 和 MITO7 试验的荟萃分析。

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

机构信息

Unità Sperimentazioni Cliniche, Istituto Nazionale Tumori - IRCCS- Fondazione G.Pascale, Napoli, Italia.

Ginecologia Oncologica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy.

出版信息

Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24.

DOI:10.1016/j.ygyno.2019.04.012
PMID:31029508
Abstract

Chemotherapy-induced neutropenia (CIN) has been associated with improved prognosis in several cancer conditions. Contrasting data have been produced in ovarian cancer.

摘要

化疗引起的中性粒细胞减少症（CIN）与几种癌症情况下的改善预后有关。在卵巢癌中得出了相互矛盾的数据。

相似文献

1
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.化疗引起的中性粒细胞减少症在前瞻性卵巢癌一线治疗中的预后作用。MITO2 和 MITO7 试验的荟萃分析。
Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24.
2
Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.PLD/奥沙利铂方案在既往卡铂/紫杉醇治疗脆弱的复发性卵巢癌患者中的耐受性。
Am J Clin Oncol. 2011 Jun;34(3):305-8. doi: 10.1097/COC.0b013e3181e1cb22.
3
Chemotherapy: A new standard combination for recurrent ovarian cancer?化疗：复发性卵巢癌的新标准组合？
Nat Rev Clin Oncol. 2010 Oct;7(10):559-60. doi: 10.1038/nrclinonc.2010.152.
4
Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?化疗引起的中性粒细胞减少症是否是卵巢癌患者的预后因素？
Acta Obstet Gynecol Scand. 2010 May;89(5):623-8. doi: 10.3109/00016341003674913.
5
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.卡铂联合聚乙二醇脂质体阿霉素与卡铂联合紫杉醇治疗铂敏感卵巢癌患者的随机 II 期研究：希腊肿瘤协作组研究。
BMC Med. 2010 Jan 7;8:3. doi: 10.1186/1741-7015-8-3.
6
[Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].聚乙二醇化脂质体阿霉素与卡铂联合紫杉醇与卡铂治疗铂敏感型卵巢癌晚期复发患者的比较
Klin Onkol. 2011;24(6):475-6.
7
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.与卡铂-紫杉醇联合治疗相比，卡铂-聚乙二醇脂质体阿霉素降低了过敏反应：GCIG CALYPSO 复发性卵巢癌试验的分析。
Gynecol Oncol. 2011 Aug;122(2):226-32. doi: 10.1016/j.ygyno.2011.04.019. Epub 2011 May 14.
8
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].聚乙二醇化脂质体阿霉素与卡铂联合治疗复发性上皮性卵巢癌
Zhonghua Fu Chan Ke Za Zhi. 2008 Nov;43(11):839-42.
9
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.聚乙二醇化脂质体阿霉素（PLD）联合卡铂治疗6至12个月内复发的卵巢癌患者的疗效：一项II期研究。
Gynecol Oncol. 2009 Sep;114(3):410-4. doi: 10.1016/j.ygyno.2009.04.037. Epub 2009 Jun 10.
10
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.化疗引起的中性粒细胞减少作为晚期卵巢癌生存的生物标志物：妇科肿瘤学组的一项探索性研究。
Gynecol Oncol. 2014 Jun;133(3):439-45. doi: 10.1016/j.ygyno.2014.03.013. Epub 2014 Mar 20.

引用本文的文献

1
The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer.初始中性粒细胞减少和中性粒细胞动态变化在铂耐药卵巢癌个体化化疗中的作用
Medicina (Kaunas). 2025 Mar 7;61(3):470. doi: 10.3390/medicina61030470.
2
"Moderate" adjuvant chemotherapy-induced leukopenia is beneficial for survival of patients with early breast cancer: a retrospective study.“中度”辅助化疗引起的白细胞减少有利于早期乳腺癌患者的生存：一项回顾性研究。
BMC Cancer. 2023 Dec 13;23(1):1227. doi: 10.1186/s12885-023-11680-x.
3
Incidence, consequences, and predictors of serious chemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma.
鼻咽癌患者严重化疗诱导性血小板减少症的发生率、后果和预测因素。
Cancer Med. 2023 Jul;12(13):14084-14093. doi: 10.1002/cam4.6062. Epub 2023 May 22.
4
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.成人化疗所致中性粒细胞减少症的当前管理：要点和新挑战：中国抗癌协会肿瘤支持治疗专业委员会、中国抗癌协会临床化疗专业委员会。
Cancer Biol Med. 2020 Nov 15;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15.
5
HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.HOXB4 通过 DHDDS 促进卵巢癌的恶性进展。
BMC Cancer. 2020 Mar 16;20(1):222. doi: 10.1186/s12885-020-06725-4.
6
Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer.早发性中性粒细胞减少症：预测浆液性卵巢癌患者化疗敏感性和预后良好的有用指标。
BMC Cancer. 2020 Feb 12;20(1):116. doi: 10.1186/s12885-020-6609-x.